Cost and duration of patent litigation


With more patents issuing than ever before, there is a greater likelihood that your company will become a party to patent litigation. It is important, therefore, to familiarise yourself with the basic factors affecting the cost and duration of patent litigation.

The average patent litigation lasts about two years and costs about $3 million. An appeal can add another $2 million and one year to that estimate.

Patent litigation cost and duration depend on a variety of factors. Our firm represented a generic pharmaceutical company in litigation involving a product with over $1...


Please log in to read the rest of this article.

New to Managing Intellectual Property? Take advantage of one week’s FREE access and become a Managing IP member today. It’s free to join and the benefits start straight away.

Already registered?

Please make sure you log in to read the rest of the article.

Log in

Join us now

Gain 7 days FREE access when you register now.

Join here

profile

Managing IP

ManagingIP

ManagingIP profile

Join us on Tuesday for a Twitter Q&A with @theIPO's @RMW136 on innovation and IP 4pmBST/11amEST. Any questions you want to ask her? #MIP50

Sep 19 2014 11:21 ·  reply ·  retweet ·  favourite
ManagingIP profile

Three new patent attorney partners for @finneganIPLaw in London - details http://t.co/bfciijxZUU

Sep 18 2014 01:52 ·  reply ·  retweet ·  favourite
ManagingIP profile

RT @OliviaLuk1: @ManagingIP can't do it but that sounds awesome for a younger professional!

Sep 18 2014 01:46 ·  reply ·  retweet ·  favourite
More from the Managing IP blog


AIPPI Congress News 2014

Read this year's AIPPI Congress News - published daily by Managing IP direct from the AIPPI Annual Meeting in Toronto
null null null

September 2014

The surprising rise of the PTAB

Patent owners have been shocked at how popular IPR proceedings at the PTAB have proven. As the USPTO mulls over changes and the Federal Circuit braces itself for a deluge of appeals, Michael Loney reports on how the PTAB is likely to evolve



Most read articles

Supplements